Ibrutinib, venetoclax plus CD20 monoclonal Ab: Initial results of OASIS II, a prospective randomized phase 2 trial in previously untreated mantle cell lymphoma patients. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results